Join
Live feed
·
PRReleasevia Quantisnow
Annexon Inc. logo

Annexon Biosciences Reports Promising Interim Phase 2 Data Showing Improvement in Clinical Measures with ANX005 in Huntington's Disease Following Six-Month Treatment

ByQuantisnow·Wall Street's wire, on your screen.
ANNX· Annexon Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ANNX (Annexon Inc.) and more on Quantisnow.